Posted by Michael Wonder on 30 Oct 2015
Bayer receives EU approval for Eylea for the treatment of visual impairment secondary to myopic choroidal neovascularization
30 October 2015 - Bayer has received approval from the European Commission for the eye drug Eylea (aflibercept solution for injection into the eye) in a fifth indication.
For more details, go to: http://www.news.bayer.com/baynews/baynews.nsf/id/Bayer-Receives-EU-Approval-EYLEA-Treatment-Visual-Impairment-Secondary-Myopic-Choroidal?OpenDocument&sessionID=1446232853
